PureTech Health plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Robert Lyne Sharon Barber-Lui John LaMattina Michele Holcomb, was filed 09 Jul 2026.
PureTech Health plc: what insiders have been doing
Every trade that managers of PureTech Health plc disclose to RNS (LSE) is tracked on this page. The company sits in the Health Care sector. In the past year (22 October 2025 to 22 October 2026), 5 filings came from 5 insiders.
No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €206k, made by 2 insiders. No amount is published for 1 filing, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 2 chief executives. Biggest ticket of the year: €206k, bought by Robert Lyne Sharon Barber-Lui John LaMattina Michele Holcomb and made public on 9 July 2026 (0.063% of market cap).
Compared with its exchange (832 companies, median 6 filings), a count of 5 filings is below the norm. Since 2016, the database holds 4 purchases and 1 sale by insiders of the company.
The clock since the last published purchase (9 July 2026) now reads 122 days. Between a trade and the moment it shows up on RNS (LSE), the median delay is 1 day. Under the UK Market Abuse Regulation, managers have three business days to notify their trades.
Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -7.0%Entry £1.23 · Close 16 Oct 2026 £1.15
- +14.2%Entry £1.38 · Close at T+365 £1.57
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate PureTech Health plc Strong Buy (bullish), based on 5 analysts. Average price target: £2.98.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 0.012 sharesLondon Stock Exchange (XLON)ISIN GB00BY2Z0H74RNS:9728357
- ◆John LaMattina Robert Langer Kiran Mazumdar-Shaw Sharon Barber-Lui Michele Holcomb0RNS0.015 sharesLondon Stock Exchange (XLON)ISIN GB00BY2Z0H74RNS:9699371
- 0.011 sharesLondon Stock Exchange (XLON)ISIN GB00BY2Z0H74RNS:9675594
- 147,849 shares@ £1.190.063% mcap100.0% of flowLondon Stock Exchange (XLON)ISIN GB00BY2Z0H74RNS:9659722Canonical exit: 6 Oct 2026 (T+90)
- 0London Stock Exchange (XLON)RNS:005256f7-9354-47fa-bb9c-8326e9b52890Canonical exit: 6 Oct 2026 (T+90)
- 0Outside of a trading venueISIN GB00BY2Z0H74RNS:5412170
- 0London Stock Exchange (XLON)ISIN GB00BY2Z0H74RNS:5243055
- 18,000 sharesOutside of a trading venueFCA-NSM:4603515
- 205,000 sharesOutside of a trading venueFCA-NSM:3820762
- 308,876 sharesOutside of a trading venueFCA-NSM:3789300
- 305,296 sharesOutside of a trading venueFCA-NSM:3767292
- 1,400,000 sharesOutside a trading venueFCA-NSM:LSE20180525070008_13655046_20200330111431346_4873
- 25,000 shares@ £1.37100.0% of flowLondon Stock Exchange (XLON)FCA-NSM:LSE20170907170001_13355822_20200330131540110_5079Canonical exit: 3 Dec 2017 (T+90)
- 15,000 shares@ £1.3837.7% of flowLondon Stock Exchange (XLON)FCA-NSM:LSE20170904070006_13350023_20200330131539937_1291Canonical exit: 28 Nov 2017 (T+90)
- 471,118 sharesOutside a trading venueFCA-NSM:LSE20170731070007_13312328_20200330131519842_20990
- 1,200,000 sharesOutside a trading venueFCA-NSM:LSE20170413070009_13193226_20200330131459455_9363
- 309,344 sharesOutside a trading venueFCA-NSM:LSE20161222070010_013075587_20200330143549448_16049
- 150,000 sharesOutside a trading venueFCA-NSM:LSE20160927070011_012979521_20200330143620039_19727
- 735,452 sharesOutside a trading venueFCA-NSM:LSE20160712150003_012889728_20200330143558182_9049
19 of 19 declarations
About PureTech Health plc
PureTech Health plc is a biopharmaceutical company focused on discovering and developing new therapies for serious diseases. It employs an innovative approach to identify and commercialize therapeutic products.
